OOOlajumoke Evangelina Owokotomo

Olajumoke Evangelina Owokotomo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olajumoke Evangelina Owokotomo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of Microbiome Biomarkers in Intervention Studies

    by Olajumoke Evangelina Owokotomo, Rudradev Sengupta, Ziv Shkedy

    Aims There has been an increased interest in studying the association between microbial communities and different diseases and in discovering microbiome biomarkers. This association is pivotal to discover such biomarkers. In this paper, we present a unified modelling approach that can be used to detect and develop microbiome biomarkers for different clinical responses of interest at different levels of the microbiome ecosystem. Methods and results We extended the methodology rooted in the information theory and joint modelling approaches for the evaluation of surrogate endpoints in randomized clinical trials to the high-dimensional microbiome setting. The unified modelling approach introduced in this paper allows for detecting biomarkers associated with a clinical response of interest, adjusting for the intervention applied to the subjects. For some microbiome features, the association is driven by the treatment, while for others, the association reflects the correlation between the microbiome biomarker and the clinical response of interest. Conclusions The results have demonstrated that biomarkers can be identified at different levels of the microbiome phylogenetic tree using various measures as biomarkers.


  • Open Access

    Modelling the positive testing rate of COVID-19 in South Africa Using A Semi-Parametric Smoother for Binomial Data

    by Olajumoke Evangelina Owokotomo, Samuel Manda, Adetayo Kasim, Jurgen Claesen, Ziv Shkedy, Tarylee Reddy

    The current outbreak of COVID-19 is a major pandemic that has shaken up the entire world in a short time. South Africa has the highest number of COVID-19 cases in Africa and understanding the country’s disease trajectory is important for government policy makers to plan the optimal COVID-19 intervention strategy. The number of cases is highly correlated with the number of COVID-19 tests undertaking. Thus, current methods of understanding the COVID-19 transmission process in the country based only on the number of cases can be misleading. In light of this, we propose to estimate both the probability of positive cases per tests conducted (the positive testing rate) and the rate in which the positive testing rate changes over time (its derivative) using a flexible semi-parametric model. We applied the method to the observed positive testing rate in South Africa with data obtained from March 5th to September 2nd 2020. We found that the positive testing rate was declining from early March when the disease was first observed until early May where it kept on increasing. In the month of July 2020, the infection reached its peak then its started to decrease again indicating that the intervention strategy is effective. From mid August, 2020, the rate of change of the positive testing rate indicates that decline in the positive testing rate is slowing down, suggesting that a less effective intervention is currently implemented.

  • Open Access

    The plasma glutamate concentration as a complementary tool to differentiate benign PET-positive lung lesions from lung cancer

    by K. Vanhove, P. Giesen, O. E. Owokotomo, L. Mesotten, E. Louis, Z. Shkedy, M. Thomeer, P. Adriaensens

    Pulmonary imaging often identifies suspicious abnormalities resulting in supplementary diagnostic procedures. This study aims to investigate whether the metabolic fingerprint of plasma allows to discriminate between patients with lung inflammation and patients with lung cancer. Metabolic profiles of plasma from 347 controls, 269 cancer patients and 108 patients with inflammation were obtained by 1H-NMR spectroscopy. Models to discriminate between groups were trained by PLS-LDA. A test set was used for independent validation. A ROC curve was built to evaluate the diagnostic performance of potential biomarkers. Sensitivity, specificity, PPV and NPV of PET-CT to diagnose cancer are 96, 23, 76 and 71%. Metabolic profiles differentiate between cancer and inflammation with a sensitivity of 89%, a specificity of 87% and a MCE of 12%. Removal of the glutamate metabolite results in an increase of MCE (38%) and a decrease of both sensitivity and specificity (62%), demonstrating the importance of glutamate for discrimination. At the cut-off point 0.31 on the ROC curve, the relative glutamate concentration discriminates between cancer and inflammation with a sensitivity of 85%, a specificity of 81%, and an AUC of 0.88. PPV and NPV are 92 and 69%. In PET-positive patients with a relative glutamate level ≤ 0.31 the sensitivity to diagnose cancer reaches 100% with a PPV of 94%. In PET-negative patients, a relative glutamate level > 0.31 increases the specificity of PET from 23% to 58% and results in a high NPV of 100%. In case of discrepancy between SUVmax and the glutamate concentration, lung cancer is missed in 19% of the cases. This study indicates that the 1H-NMR-derived relative plasma concentration of glutamate allows discrimination between lung cancer and lung inflammation. A glutamate level ≤ 0.31 in PET-positive patients corresponds to the diagnosis of lung cancer with a higher specificity and PPV than PET-CT. Glutamate levels > 0.31 in patients with PET negative lung lesions is likely to correspond with inflammation. Caution is needed for patients with conflicting SUVmax values and glutamate concentrations. Confirmation is needed in a prospective study with external validation and by another analytical technique such as HPLC-MS.